Kevin K. Buckbee - Feb 26, 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
SVP, CONTROLLER
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Kevin K. Buckbee
Stock symbol
ABBV
Transactions as of
Feb 26, 2025
Transactions value $
-$3,853,372
Form type
4
Date filed
2/28/2025, 05:00 PM
Previous filing
Feb 18, 2025
Next filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Sale -$546K -2.68K -17.51% $203.40 12.6K Feb 26, 2025 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $911K +9.74K +77% $93.50 22.4K Feb 26, 2025 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $691K +6.52K +29.14% $105.92 28.9K Feb 26, 2025 Direct
transaction ABBV Common Stock, $0.01 par value Sale -$3.31M -16.3K -58.58% $203.41 11.5K Feb 26, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to buy) Options Exercise -$911K -9.74K -80.41% $93.50 2.37K Feb 26, 2025 Common Stock 9.74K $93.50 Direct F3
transaction ABBV Option (Right to buy) Options Exercise -$691K -6.52K -70.01% $105.92 2.79K Feb 26, 2025 Common Stock 6.52K $105.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.39 to $203.48, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reporting person transferred 1,150 shares of common stock to his former spouse pursuant to a domestic relations order since his last ownership report and has ceased to be the beneficial owner of such shares.
F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.